Science - Molecure

Informacja o wstępnych danych zaprezentowanych przez Calithera Biosciences, dotyczących bezpieczeństwa i skuteczności z badania klinicznego oceniającego inhibitor arginazy INCB001158

W dniach 15-17 stycznia 2021 odbyło się wirtualne sympozjum poświęcone nowotworom przewodu pokarmowego zorganizowane przez American Society of Clinical Oncology (ASCO), w trakcie którego zostały zaprezentowane wstępne dane dotyczące bezpieczeństwa i skuteczności z badania klinicznego oceniającego

OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients

OncoArendi Therapeutics SA today signed an agreement with VIB, one of the world leading life science research institutes. The scope of this research collaboration focuses on the role of chitinase and chitinase-like-proteins (CLPs) in COVID-19 and

OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients

OncoArendi Therapeutics SA today signed an agreement with VIB, one of the world leading life science research institutes. The scope of this research collaboration focuses on the role of chitinase and chitinase-like-proteins (CLPs) in COVID-19 and

Publikacja o polskim sektorze biotechnologii w renomowanym czasopiśmie naukowym Technology Transfer and Entrepreneurship wydawanym przez Bentham Science

W najnowszym numerze pisma Technology Transfer and Entrepreneurship, wydawanego przez Bentham Science, został opublikowany zbiór artykułów na temat powstania i perspektyw dla polskiego sektora biotechnologii, w tym osobny artykuł poświęcony OncoArendi Therapeutics autorstwa Marcina Szumowskiego, Prezesa

Molecure’s success in development of the mRNA discovery platform

- Molecure confirms that small molecules designed to target mRNA inhibit translation of the encoded protein relevant in cancer - Proof-of-Concept has been demonstrated in a cell assay - Reaching the PoC stage for the first

Luke O’Neill

Luke O’Neill is Professor of Biochemistry in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute at Trinity College Dublin, Ireland. He is a world expert on innate immunity and inflammation. His main research interests

Luke O’Neill

Luke O’Neill jest profesorem biochemii w Trinity Biomedical Sciences Institute w Trinity College w Dublinie na Wydziale Biochemii i Immunologii. Jest światowym ekspertem w dziedzinie wrodzonej odporności i stanów zapalnych. Jego główne zainteresowania badawcze obejmują receptory

The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch

Molecure can proceed with clinical trials in the U.S.A – Phase II proof-of-concept study will be the first to treat patients suffering from pulmonary sarcoidosis with OATD-01 In the coming weeks Molecure will also seek the

Molecure completes successful Secondary Public Offering of approximately USD 12 million with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies

Closing of equity offering of 2,776,000 series H shares by private placement, offered within the authorised capital, at an issue price of PLN 18 per share Series H shares were subscribed for by 35 investors, new

Search Results for: Science

Informacja o wstępnych danych zaprezentowanych przez Calithera Biosciences, dotyczących bezpieczeństwa i skuteczności z badania klinicznego oceniającego inhibitor arginazy INCB001158

OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients

OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients

Publikacja o polskim sektorze biotechnologii w renomowanym czasopiśmie naukowym Technology Transfer and Entrepreneurship wydawanym przez Bentham Science

Molecure’s success in development of the mRNA discovery platform

Luke O’Neill

Luke O’Neill

The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch

Molecure completes successful Secondary Public Offering of approximately USD 12 million with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies